Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Adverse events will be closely watched when full data are reported.
